2018

1. A European, Observational Study of Endocrine Therapy Administration in Patients With an Initial Diagnosis of Hormone Receptor-Positive Advanced Breast Cancer

   Clinical Breast Cancer, Vol. 18, Núm. 4, pp. e613-e619

2. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

   EMBO Molecular Medicine, Vol. 10, Núm. 12

3. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

   Annals of Oncology, Vol. 29, Núm. 5, pp. 1203-1210